Simple innovations to the VenaSeal™ closure system mean greater* impact for you and your practice, and the same great outcomes you expect — such as a demonstrated 94.6% closure rate at 5 years.1-3Learn More
The ClosureFast™ procedure, with its patented overlap design, is the only RFA procedure with published clinical data demonstrating long-term safety and efficacy, with a 91.9% closure rate at 5 years.4,5Learn about ClosureFast
All statements of being “greater” are as compared to previous version and procedure technique.
Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European Multicenter Cohort Study on Cyanoacrylate Embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. March 2021;9(2):329-334.
Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-sixth-month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. September 2017;5(5):658-666.
Morrison N, Gibson K, Vasquez M, et al. Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. November 2020;8(6):978-989.
Proebstle TM, Alm BJ, Göckeritz O, et al. Five-year results from the prospective European multicentre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins. Br J Surg. February 2015;102(3):212-218.
ClosureFast and ClosureFast RFS Patents. Available at www.medtronic.com/patents. Accessed March 9, 2021.